(secondQuint)A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults.

 The study will evaluate the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations, some with adjuvant, when administered alone or concomitantly with SIIV.

 Healthy male and female subjects between 60 to 85 years of age will be enrolled.

 Subjects in the sentinel cohort will receive one of two RSV vaccine formulations at one of 3 antigen dose levels or placebo.

 Subjects in the expanded cohort will receive one of two RSV vaccine formulations at one of 3 antigen dose levels with or without SIIV.

.

 A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults@highlight

The study will evaluate the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations, some with adjuvant, when administered alone or concomitantly with seasonal inactivated influenza vaccine (SIIV).

